ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis' innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting.At Eyecelerator, Riad Sherif, MD, Oculis' Chief Executive Officer, will provide an update on the Company's innovative late-stage pipeline. Featured updates will include the acceleration of Privosegtor into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy following a positive meeting with the U.S. Food and Drug Administration (FDA); an update on the Phase 3 DIAMOND program with OCS-01 eye drops for diabetic macular edema with expected topline readouts in Q2 2026; and an update on the upcoming PREDICT-1 registrational trial with a genotype-based approach to investigate Licaminlimab in dry eye disease, anticipated to start in Q4 2025.Surrounding AAO, Oculis will actively participate and support multiple events including Innovate Retina, the Inaugural Meeting of the Society for Artificial Intelligence in Vision and Ophthalmology (SAIVO) and the COPhy Satellite Symposium. At Innovate Retina, Arshad M. Khanani, MD, MS, FASRS, Chair of Oculis' Retina Scientific Advisory Board and Board Member of Oculis, will join a panel session to discuss the emerging role of eye drops such as OCS-01 in the future treatment paradigms for diabetic macular edema.Events details are as follows:Eyecelerator @ AAO 2025:Format: Corporate presentationSession: Presenting Company ShowcasesPresenter: Riad Sherif, MD, Chief Executive Officer Presentation date and time: Thursday, October 16, 2025; 1:15 PM ETLocation: Orange County Convention Center, Orlando, FLInnovate Retina:Format: Panel discussionSession: Session #4 - Can Eye drops Replace Intravitreal Injections?Presenter: Arshad M. Khanani, MD, MA, FASRS Presentation date and time: Thursday, October 16, 2025; 5:25 PM ET Location: Hilton, Orlando, FLSAIVO:Event date and time: Thursday, October 17, 2025; 6:00 PM ET Location: Hotel Landy, Orlando, FLCOPhy Satellite Symposium:Event date and time: Thursday, October 17, 2025; 6:30 PM ET Location: Hyatt Regency, Orlando, FLAAO Annual MeetingEvent dates: October 18-20, 2025Location: Orange County Convention Center, Orlando, FL (booth 1353)Arshad M. Khanani, MD, MA, FASRS, is a distinguished ophthalmologist who serves as Managing Partner and Director of Clinical Research at Sierra Eye Associates and Clinical Associate Professor at the University of Nevada, Reno School of Medicine. He founded Sierra Eye Associates' clinical research department, which has become one of the nation's leading clinical research centers, where he has served as principal investigator for over 100 clinical trials and contributed to over 75 scientific publications. Dr. Khanani is an elected member of the Macula Society and Retina Society and has received numerous prestigious awards including the ASRS Senior Honor Award and the ASRS Presidents' Young Investigator Award in 2021.About Privosegtor Privosegtor is a novel peptoid small molecule candidate with the potential to become the first neuroprotective therapy for acute optic neuritis (AON) and other neuro-ophthalmic diseases. The positive results in the ACUITY Phase 2 trial showed Privosegtor's potential neuroprotective effects through anatomical preservation of the retina and visual function improvements after an acute episode of optic neuritis. Consistent results were observed in animal models of neuroinflammation and neurodegeneration, where Privosegtor showed preservation of retinal ganglion cell damage and was associated with improvements in mobility (clinical function disability). Privosegtor has received Orphan Drug designation from both the FDA and the EMA for AON and is now entering registrational trials for this indication as well as a ...Full story available on Benzinga.com